The Phase 1 juMPStart clinical trial is an open-label, dose-escalation study designed to evaluate three doses of HMI-203. While three different doses will be studied, each patient will only receive a one-time intravenous dose of HMI-203. The trial is expected to enroll male patients ages 18-45 years old who have been diagnosed with Hunter syndrome and are currently receiving enzyme replacement therapy (ERT). In addition to safety endpoints, the trial plans to measure plasma I2S activity, urinary GAG levels and other peripheral disease manifestations.
You may be eligible to participate in the juMPStart study if you:
- Are a male between the ages of 18-45 years
- Have a confirmed diagnosis of MPS II
- Are currently receiving enzyme replacement therapy (ERT) as treatment for MPS II
Additional eligibility criteria will apply.